Brexit means little for biotech stocks, analyst says
Health-care stocks rally as Medicare cost-cutting not triggered
Global Spinal Cord Injury Pipeline Review, H1 2016 - Analysis, Technologies & Forecasts - Key Vendors: Athersys, Lpath, Tumorend - Research and Markets
CRISPR Therapeutics and Anagenesis Biotechnologies Announce Strategic In-Licensing and Collaboration Agreement to Develop CRISPR/Cas9-based Cell Therapies for Muscle Diseases
Recent clinical success in cystic fibrosis positions Vertex as a dominant player in this attractive rare-disease market.
Options on this firm's blockbuster cost a little but pay off big.
Following is a roundup of stocks that recently jumped to 5 stars in the last week. By way of background, we award a stock 5 stars when it trades at a suitably large discount--i.e., a margin of safety--to our fair value estimate. Thus, when a stock hits 5-star territory, we consider it an especially ...
We dive into the process for adding companies and booting them from the iconic index.
StockInvestor editor Matt Coffina and senior biotech analyst Karen Andersen discuss Gilead's growing competitive advantages.
Morningstar analysts see pharmaceuticals as 2010's hot zone for mergers and acquisitions.